AbbVie Inc
I · Análisis con IA
En breve
AbbVie researches, develops, and sells prescription medicines across multiple therapeutic areas. Their biggest focus is immunology drugs (like Skyrizi and Rinvoq) that treat autoimmune diseases, along with cancer treatments (Imbruvica, Venclexta), neuroscience medications (Vraylar, Botox, migraine drugs), and aesthetics products (facial injectables and skincare) [Yahoo Finance]. The company also sells eye care products and treatments for digestive conditions.
AbbVie is a large pharmaceutical company headquartered in Illinois that develops and sells medicines for serious diseases including autoimmune conditions, cancer, neurological disorders, and eye diseases [Yahoo Finance]. The company spun off from Abbott Laboratories in 2013 and now employs 57,000 people worldwide, generating $61.2 billion in annual revenue [Yahoo Finance]. AbbVie is successfully transitioning away from its former blockbuster drug Humira by growing newer products like Skyrizi, Rinvoq, and neuroscience treatments [Yahoo Finance].
AbbVie is financially healthy with strong cash generation, though it carries moderate debt and trades at an unusually high valuation [Yahoo Finance].
Puntuación Sentinellis
7.4/10
Financially healthy
Capitalización bursátil
$377.7B
Ingresos (12 meses)
$61.2B
II · Noticias recientes
Qué movió el precio
6 stories · ranked by relevance
- macro2026-05-19
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks
- macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- macro2026-05-19
Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer
Yahoo Finance
- macro2026-05-19
2 Reasons to Like ABBV and 1 to Stay Skeptical
Yahoo Finance
- macro2026-05-18
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
Yahoo Finance
- macro2026-05-18
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth
Yahoo Finance
Premium · gratis con cualquier cuenta
AbbVie generates about half its revenue from immunology treatments, creating significant concentration risk if this single therapeutic area faces competitive pressure or regulatory challenges [Yahoo Finance]
Riesgos
4
Oportunidades
6
Señales de alerta
2
Dirección
10
21 hallazgos más en el informe completo — gratis con cualquier cuenta.
Desbloquea el análisis completo de AbbVie Inc
Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.
- 4 riesgos, 6 oportunidades y 2 señales de alerta — cada uno con su fuente
- Más de 100 métricas financieras con gráficos y comparativas
- Resúmenes completos de noticias con enlaces a las fuentes
- Equipo directivo y remuneración
- Exportación a PDF para leer sin conexión
III · Empresas similares
También te puede interesar
Same sector · Healthcare or comparable health
¿La añades a tu lista?